首页> 美国卫生研究院文献>Stem Cells International >Analysis of Embryoid Bodies Derived from Human Induced Pluripotent Stem Cells as a Means to Assess Pluripotency
【2h】

Analysis of Embryoid Bodies Derived from Human Induced Pluripotent Stem Cells as a Means to Assess Pluripotency

机译:人类诱导的多能干细胞衍生的胚状体的分析作为评估多能性的一种手段

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Human induced pluripotent stem cells (hiPSCs) have core properties of unlimited self-renewal and differentiation potential and have emerged as exciting cell sources for applications in regenerative medicine, drug discovery, understanding of development, and disease etiology. Key among numerous criteria to assess pluripotency includes the in vivo teratoma assay that has been widely proposed as a standard functional assay to demonstrate the pluripotency of hiPSCs. Yet, the lack of reliability across methodologies, lack of definitive clinical significance, and associated expenses bring into question use of the teratoma assay as the “gold standard” for determining pluripotency. We propose use of the in vitro embryoid body (EB) assay as an important alternative to the teratoma assay. This paper summarizes the methodologies for creating EBs from hiPSCs and the subsequent analyses to assess pluripotency and proposes its use as a cost-effective, controlled, and reproducible approach that can easily be adopted to determine pluripotency of generated hiPSCs.
机译:人类诱导的多能干细胞(hiPSC)具有无限的自我更新和分化潜能的核心特性,并已成为令人兴奋的细胞来源,可用于再生医学,药物发现,对发展的了解以及疾病病因学。评估多能性的众多标准中的关键包括体内畸胎瘤测定法,该方法已被广泛提议为证明hiPSC的多能性的标准功能测定法。然而,由于缺乏方法学上的可靠性,缺乏确定的临床意义以及相关费用,使用畸胎瘤测定法作为确定多能性的“金标准”成为问题。我们建议使用体外胚状体(EB)分析作为畸胎瘤分析的重要替代方法。本文概述了从hiPSC创建EB的方法,并进行了后续分析以评估多能性,并提出了将其用作具有成本效益,可控制且可重现的方法的方法,可以轻松地确定生成的hiPSC的多能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号